SI
SI
discoversearch

Biotech / Medical
ProMetic Life Sciences
An SI Board Since April 2016
Posts SubjectMarks Bans Symbol
127 8 0 PLI
Emcee:  axial Type:  Moderated
PROMETIC LIFE SCIENCES — prometic.com

ProMetic is a biopharmaceutical corporation with globally recognized expertise in bioseparation and uses its own affinity technology for the development of best in class plasma-derived therapeutics. ProMetic is also active in developing its own novel small molecule therapeutics products. Headquartered in Laval, Canada, ProMetic has a global presence through its various sites in the UK and USA, providing both manufacturing and R&D capability. These strategic locations facilitate ProMetic’s growth globally and supports all business activity in American, European and Asian markets. ProMetic is publicly traded on TSX (Symbol: PLI) and OTCQX (Symbol: PFSCF).

ProMetic has developed core competencies in strategic fields, including:
  • Purification of biologics
  • Drug development
  • Proteomics
  • Elimination of pathogens
The business is now focused on developing its range of therapeutics from both its plasma-derived and small-molecule platform.
___________________________________________

WELCOME! —This is a moderated board. No spam, ad hominem attacks or flaming. One warning. Next time you're out, with your posts deleted.
___________________________________________
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
127Update — Prometic pipeline September 2017 [graphic] Jimaxial-last Friday
126PROMETIC REPORTS POSITIVE CLINICAL DATA FROM ONGOING PBI-4050 STUDY IN ALSTRaxial1last Tuesday
125This is an informative thread on the Stockhouse board. Recommended reading. Jiaxial-last Tuesday
124Leo, thanks for your courteous reply. With Prometic, it often seems there's axial-September 16
123Jim thanks for keeping this going! I am still long on PLI. Patience will be keLeo Fisher-September 16
122Morgan Stanley Global Healthcare Conference Monday, September 11 Listen at — caxial-September 11
121The waiting game continues. Despite the share price decline, there's been noaxial-September 11
120PROMETIC TO PRESENT AT TWO U.S. INVESTOR CONFERENCES IN SEPTEMBER LAVAL, QUEBEaxial-September 8
119What Other Types of Vouchers Exist? ' So far, two other types of voucher eaxial-August 29
118PROMETIC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM U.S. FDA FOR ITS PLASMaxial1August 29
117PROMETIC REPORTS 2017 SECOND QUARTER HIGHLIGHTS AND FINANCIAL RESULTS $101 milliaxial-August 14
116Blood agency seeking $855-million in funding to boost plasma supply, document reaxial-August 14
115PROMETIC AND SHENZHEN ROYAL ASSET MANAGEMENT CLOSE TRANSACTION FOR JOINT VENTURaxial-August 14
114PROMETIC TO REPORT ITS SECOND QUARTER 2017 FINANCIAL RESULTS AND TO HOLD CONFEREaxial-August 8
113PROMETIC ANNOUNCES POSITIVE LONG TERM CLINICAL DATA ON RYPLAZYMTM IN PLASMINOGEaxial-July 11
112FDA outlines ‘Innovation Initiative,’ Cures plans to speed up drug development axial-July 10
111Email from Pierre Laurin [ Original here. — *Note*— IMO, after years of readingaxial-July 10
110Response from Fred Dumais re: current status ... content edited for clarity. Oaxial-July 7
109PROMETIC ANNOUNCES CLOSING OF EQUITY OFFERINGS FOR AGGREGATE GROSS PROCEEDS OF $axial-July 6
108Gottlieb's Aggressive Plans to Streamline the Orphan Drug Review Process &axial-June 22
107Well that's disappointing! In that last CC, as I heard it, in response toCush1June 15
106PROMETIC ANNOUNCES $53 MILLION BOUGHT DEAL OFFERING 'LAVAL, QUEBEC, CANADA axial-June 15
105NEW DATA PRESENTED BY PROMETIC AT ADA’S SCIENTIFIC SESSIONS VALIDATES PBI-4050axial-June 12
104From an MD/Prometic investor ... Intensive Care Off Label Indications ' Fraxial1May 23
103PROMETIC PRESENTS NEW DATA ON PBI-4050 AND PLASMINOGEN AT THE AMERICAN THORACIC axial-May 23
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.